Intec Pharma (NTEC) IPO Opens Flat

Today's IPO for Intec Pharma (NASDAQ: NTEC) opened for trading at $6.00 per share, after pricing 5,025,000 of its ordinary shares at a price to the public of $6.00 per ordinary share.

Maxim Group LLC and Roth Capital Partners are acting as joint book-running managers for the offering.

Intec Pharma Ltd. is a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline currently includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CDLD, is being developed for the indication of treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, and Accordion Pill Zaleplon, or AP-ZP, is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance.

You May Also Be Interested In